To the full analysis
Buyback calculator for Zevra Therapeutics
Zevra Therapeutics stock: key metrics
ZVRAZevra Therapeutics had an operating margin of −4% and a return on invested capital (ROIC) of −14.2% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2012 | no data | no data | no data |
| 2013 | no data | no data | no data |
| 2014 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | 77.1% | −158.4% | −191.0% |
| 2020 | 90.2% | −42.2% | −96.0% |
| 2021 | 92.8% | 27.0% | −29.9% |
| 2022 | 97.8% | −418.9% | −263.5% |
| 2023 | 89.3% | −180.6% | −167.7% |
| 2024 | 68.6% | −368.5% | −446.9% |
| 2025 | 84.5% | −4.0% | 78.2% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2012 | 11.2% | no data | −2.4% |
| 2013 | 21.5% | no data | −100.0% |
| 2014 | 100.6% | no data | −100.0% |
| 2015 | 200.0% | −58.7% | −98.1% |
| 2016 | 88.3% | −45.9% | −19.5% |
| 2017 | 75.4% | −43.0% | −82.7% |
| 2018 | 84.8% | no data | −100.0% |
| 2019 | 32.9% | no data | −100.0% |
| 2020 | 19.2% | −97.0% | −100.0% |
| 2021 | −6.7% | 9.2% | −6.4% |
| 2022 | −35.6% | −28.4% | −23.2% |
| 2023 | −74.4% | −32.1% | −26.7% |
| 2024 | −100.0% | −49.0% | −59.2% |
| 2025 | 53.8% | −14.2% | 29.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.